

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

1. EGFR exon 20 insertion mutations are more common in women and in people of Asian heritage
2. There are concerns that lung cancer and the symptoms of lung cancer are associated with stigma, particularly in Asian communities, which could contribute to diagnosis or treatment delaying behaviour.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Differences in prevalence of a condition in different groups cannot be addressed by a technology appraisal committee in an appraisal. The committee will consider whether there are any relevant equality considerations affecting its decision making as part of the appraisal.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Health Technology Evaluation: Scoping
Equality impact assessment for the Health Technology Evaluation of amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]

No changes to the draft scope have been agreed to highlight these issues.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No.

Approved by Associate Director (name): Ian Watson

Date: 10/07/2024